Immuneering Corporation (IMRX) PT Lowered to $16 at Guggenheim
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts IMRX Hot Sheet
Price: $3.81 +3.53%
Rating Summary:
8 Buy, 3 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 15 | Down: 23 | New: 12
Rating Summary:
8 Buy, 3 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 15 | Down: 23 | New: 12
Join SI Premium – FREE
Guggenheim analyst Michael Schmidt lowered the price target on Immuneering Corporation (NASDAQ: IMRX) to $16.00 (from $30.00) while maintaining a Buy rating.
You May Also Be Interested In
- Immuneering to present atebimetinib data at 2026 EORTC-NCI-AACR
- Cinemark Holdings (CNK) PT Raised to $45 at StoneX
- DigitalOcean (DOCN) PT Lowered to $100 at UBS
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
